

**MEDIA RELEASE**

**Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy's Laboratories**

**Atlanta, USA / Ahmedabad, India, 04<sup>th</sup> March 2025** – Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed agreements today to acquire a basket of **14** Abbreviated New Drug Applications (‘ANDAs’) from **Dr. Reddy's Laboratories** and its applicable affiliates (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter “DRL”).

The basket acquired, comprises of **13** ANDAs, which are approved by the USFDA and **1** ANDA, which is pending approval from the USFDA.

The addressable opportunity of the acquired ANDAs in the USA is approx. **USD 421 Million (MAT December 2024)\* as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.**

The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.

Commenting on the acquisition, **Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said:

*“We are glad to announce the acquisition of a basket of products from Dr Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general category of products.*

*These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics.*

*This Portfolio of products significantly increases our products offering in the US, and also it has a significant value in other Regulated and Semi-Regulated markets of the world.”*

*\* Source: IQVIA Database*

*# Source: Symphony Database*

**About Senores Pharmaceuticals Limited:**

Senores Pharmaceuticals Limited ('Senores') is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 27 ANDA and 21 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 260 product registrations and 530 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant C other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong RCD capabilities to drive differentiated product portfolio across 3 RCD sites (1 in the USA and 2 in India).

**Safe Harbor Statement:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information, please contact:**

---

**Company: Senores Pharmaceuticals Limited**  
CIN: U24290GJ2017PLC100263**Mr. Deval Shah**Email: [investors@senorespharma.com](mailto:investors@senorespharma.com)For updates and specific queries,  
please visit[www.senorespharma.com](http://www.senorespharma.com)**Investor Relations: Strategic Growth Advisors**  
CIN: U74140MH2010PTC204285**Mr. Sagar Shroff / Mr. Tanay Shah**

M: +91 98205 19303 / +91 98333 91899

E-mail: [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net) /[tanay.shah@sgapl.net](mailto:tanay.shah@sgapl.net) For updates and specific queries,please visit [www.sgapl.net](http://www.sgapl.net)